| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | BRD-K99584050 | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | XMD11-85h | GDSC1000 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | GW843682X | GDSC1000 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | fluvastatin | CTRPv2 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0024 | 0.9 |